News articles about GTX (NASDAQ:GTXI) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GTX earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.24675027881 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
GTX (NASDAQ GTXI) traded up $0.25 during trading hours on Monday, reaching $11.81. The company’s stock had a trading volume of 71,700 shares, compared to its average volume of 57,289. GTX has a 1-year low of $2.73 and a 1-year high of $13.35. The company has a market cap of $254.41, a P/E ratio of -6.75 and a beta of 1.77.
GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). equities analysts forecast that GTX will post -1.61 earnings per share for the current fiscal year.
In other GTX news, insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $11.33, for a total value of $35,009.70. Following the completion of the sale, the insider now directly owns 31,111 shares in the company, valued at approximately $352,487.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Henry Patton Doggrell sold 4,965 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $11.33, for a total value of $56,253.45. Following the sale, the vice president now owns 54,804 shares of the company’s stock, valued at $620,929.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,364 shares of company stock worth $174,074. Corporate insiders own 41.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “GTX (GTXI) Given Daily Coverage Optimism Rating of 0.14” was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-gtx-gtxi-stock-price/1818461.html.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.